Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle

Liver

Volumn 18, Issue 1, 1998, Pages 60-66

  Chenoufi, Norchen ^a,b   Baffet, Georges ^a   Drénou, Bernard ^b   Cariou, Sandrine ^a   Desille, Mirelle ^a   Clément, Bruno ^a   Brissot, Pierre ^a,b   Lescoat, Gerard ^a   Loréal, Olivier ^a  

^a INSERM   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cell proliferation; Deferoxamine; DNA synthesis; Iron; Porcine hepatocyte cultures

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; HISTONE H1; INSULIN; IRON; NUCLEAR PROTEIN; PHOSPHOTRANSFERASE;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; FETAL CALF SERUM; FLOW CYTOMETRY; IRON CHELATION; LIVER CELL; LIVER CELL CARCINOMA; MITOSIS; NONHUMAN; SWINE;

EID: 0031907565     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1998.tb00128.x     Document Type: Article

References (45)

1. HANN H W L, STAHLHUT M W. HANN C L. Effect of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 1990; 11: 566-9.
2. KIM D Y, KIM W H, KANG J K, PARK S, KWON O H. The mechanism of antiproliferative effect of desferrioxamine on human hepatoma cell lines. Yonsei Med J 1994; 35: 62-71.
3. LUCAS J J, SZEPESI A, DOMENICO J, et al. Effect of iron depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33 cdk2 kinase. Blood 1995; 86: 2268-80.
4. BOMFORD A, ISAAC J, ROBERTS S, EDWARDS A, YOUNG S, WILLIAMS R. The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells. Biochem J 1986; 236: 243-9.
5. BRODIE C, SIRIWARDANA G, LUCAS J, et al. Neuroblastoma sensitivity to growth inhibition by desferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 1993; 53: 3968-75.
6. HOYES K P, PORTER J B. Subcellular distribution of desferrioxamine and hydroxypyridin-4 one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993; 85: 393-400.
7. HELSON L. In vivo effects of repeated exposure of human neuroblastoma cell lines to deferoxamine. Anticancer Res 1991; 11: 409-10.
8. BLATT J, STITELY S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res 1987; 47: 1749-50.
9. BECTON D L, BRYLES P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 1988; 48: 7189-92.
10. POPPER H. Pathological aspects of cirrhosis. Am J Pathol 1977; 87: 228-58.
11. FANG J W, BIRD G L, NAKAMURA T, DAVIS G L, LAU J Y. Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis. Lancet 1994; 343: 820-3.
12. CASTTLLA A, PRIETO J, FAUSTO N. Transforming growth factors β1 and a in chronic liver diseases. N Engl J Med 1991; 324: 933-40.
13. YAMAGUCHI K, NALESNIK M A, MICHALOPOULOS G K. Hepatocyte growth factor mRNA in human liver cirrhosis as evidenced by in situ hybridization. Scand J Gastroenterol 1996; 31: 921-7.
14. DEUGNIER Y M, CHARALAMBOUS P, LE QUILLEUC D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18: 1363-9.
15. DEUGNIER Y, TURLIN B, LE QUILLEUC D, et al. Reappraisal of liver siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Path 1997; 21: 669-75.
16. TURLIN B, JUGUET F, MOIRAND R, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a non cirrhotic liver. Hepatology 1995; 22: 446-50.
17. WEGNER H, SCHARECK W, BAYER-HELMS H, GEBHARDT R. Different proliferative potential of rat and pig hepatocytes in pure primary culture and coculture. Eur J Cell Biol 1992; 58: 411-7.
18. NAIK S, TRENKLA D, SANTANGINI H, PAN J, JAUREGUI H O. Isolation and culture of porcine hepatocytes for artificial liver support. Cell Transplant 1996; 5: 107-15.
19. JOLY A, DESJARDINS J F, FREMOND B, et al. Survival, proliferation, and functions of porcine hepatocytes encapsulated in coated alginate beads: a step toward a reliable bioartificial liver. Transplantation 1997; 63: 795-803.
20. GUGUEN-GUILLOUZO C, CAMPION J P, BRISSOT P, et al. High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol Int Rep 1982; 6: 625-8.
21. LOYER P, CARIOU S, GLAISE D, BILODEAU M, BAFFET G, GUGUEN-GUILLOUZO C. Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of amitogen restriction point in mid-late G1. J Biol Chem 1996; 271: 11484-92.
22. CHENOUFI N, HUBERT N, LORÉAL O, et al. Inhibition of iron toxicity in rat hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94. J Hepatol 1995; 23: 166-73.
23. TWEXTYMANN P R, LUSCOMBE A. A study of some variables in tetrazolium dye (MU) based assay for cell growth and chemosensitivity. Br J Cancer 1987; 56: 279-85.
24. DIGNAM J D, LEBOVITZ R M, ROEDER R G. Accurate transcription initiated by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res 1983; 11: 1475-89.
25. LOYER P, GLAISE D, CARIOU S, MEIJER L, GUGUEN-GUILLOUZO C. Expression and activation of cdks (1 and 2) and cyclins in the cell cycle progression during liver regeneration. J Biol Chem 1994; 269: 2491-500.
26. CAZZOLA M, BERGAMASCHI G, DEZZA L, AROSIO P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990; 75: 1903-19.
27. HANN H W, KIM C Y, LONDON W T, BLUMBERG B S. Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma. Int J Cancer 1989; 43: 376-9.
28. LI A P, MYERS C A, ROQUE M A, KAMINSKI D L. Epidermal growth factor, DNA synthesis and human hepatocytes. Cell Dev Biol 1991; 27: 831-3.
29. ISMAIL T, HOWL J, WHEATLEY M, MCMASTER P, NEUBERGER J M, STRAIN A J. Growth of normal human hepatocytes in primary culture; effect of hormones and growth factors on DNA synthesis. Hepatology 1991; 14: 1076-82.
30. STRAIN A J, ISMAIL T, TSUBOUCHI H, ARAKAKI N, HISHIDA T. Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest 1991; 87: 1853-7.
31. HOFFMANN B, PIASECKI A, PAUL D. Proliferation of fetal rat hepatocytes in response to growth factors and hormones in primary cultures. J Cell Physiol 1989; 139: 654-62
32. CHENOUFI N, LORÉAL O, DRÉNOU B, et al. Iron may induce DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J Hepatol 1997; 26: 650-8.
33. FLOOD A E, RUTHERFORD P P, WESTON E W. Nuclear ploidy in mammalian parenchymal liver cells. Nature 1967; 214: 1050-1.
34. STYLES J, ELLIOTT B M, LEFEVRE P A, et al. Irreversible depression in the ratio of tetraploid: diploid liver nuclei in rats treated with 3′-methyl-4-dimethylaminoazobenzene (3′M). Carcinogenesis 1985; 6: 21-8.
35. MARX J J M, VAN ASBECK B S. Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 1996; 95: 49-62.
36. HOFFBRAND A V, GANESHAGURU K, HOOTON W L, TATERSALL M H N. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976; 33: 517-26.
37. LEDERMAN H M, COHEN A, LEE J W W, FREEDMAM M H, GELFAND E W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748-53.
38. HANN H W L, STAHLHUT M W, BLUMBERG B S. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 1988; 48: 4168-70.
39. YOSHIJI H, NAKAE D, KINUGASA T, et al. Inhibitory effect of dietary iron deficiency on the induction of putative preneoplastic foci in rat liver initiated with diethylnitrosamine and promoted by phenobarbital. Br J Cancer 1991; 64: 839-42.
40. HANN H W L, STAHLHUT M W, RUBIN R, MADDREY W C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992; 70: 2051-6.
41. LINDNER P, NAREDI P, PETERSON A, HAFSTRÖM L. Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth. Int J Cancer 1995; 63: 592-6.
42. HIROTA N, WILLIAMS G M. Ultrastructural abnormalities in carcinogen-induced hepatocellular altered foci identified by resistance to iron accumulation Cancer Res 1982; 42: 2298-2309
43. CARTHEW P, NOLAN B M, SMITHA A G, EDWARDS R E. Iron promotes DEN initiated GST-P foci in rat liver. Carcinogenesis 1997; 18: 599-603.
44. DONFRANCESCO A, DEB G, DOMINICI C, PILEGGI D, CASTELLO M, HELSON L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929-30.
45. HIDER R C, CHOUDHURY R, RAI B L, DEHKORDI L S, SINGH S. Design of orally active iron chelators. Acta Haematol 1996; 95: 6-12.